SG11202110085TA - Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof - Google Patents

Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Info

Publication number
SG11202110085TA
SG11202110085TA SG11202110085TA SG11202110085TA SG11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA SG 11202110085T A SG11202110085T A SG 11202110085TA
Authority
SG
Singapore
Prior art keywords
preparation
method therefor
btk inhibitor
ring derivative
pharmaceutical application
Prior art date
Application number
SG11202110085TA
Inventor
Chen Zhang
Yuting Liao
Jianmin Wang
Guozhi Zhu
Fei Ye
Pingming Tang
Xiaogang Chen
Zhenggang Huang
Shoutao Wu
Yao Li
Pangke Yan
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of SG11202110085TA publication Critical patent/SG11202110085TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202110085TA 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof SG11202110085TA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201910454977 2019-05-31
CN201910706239 2019-08-02
CN201910997078 2019-10-25
CN201911291561 2019-12-16
PCT/CN2020/093455 WO2020239103A1 (en) 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Publications (1)

Publication Number Publication Date
SG11202110085TA true SG11202110085TA (en) 2021-10-28

Family

ID=73553513

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110085TA SG11202110085TA (en) 2019-05-31 2020-05-29 Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Country Status (13)

Country Link
US (1) US11542266B1 (en)
EP (1) EP3978496A4 (en)
JP (1) JP2022534650A (en)
KR (1) KR20220016049A (en)
CN (2) CN118027041A (en)
AU (1) AU2020281410A1 (en)
BR (1) BR112021024131A2 (en)
CA (1) CA3133004A1 (en)
IL (1) IL287332A (en)
MX (1) MX2021012756A (en)
SG (1) SG11202110085TA (en)
TW (1) TWI762939B (en)
WO (1) WO2020239103A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978496A4 (en) * 2019-05-31 2022-08-17 Haisco Pharmaceuticals Pte. Ltd. Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
CN115052594B (en) * 2020-01-29 2024-07-16 福宏治疗公司 Compounds and uses thereof
WO2021184154A1 (en) 2020-03-16 2021-09-23 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
US20230248833A1 (en) 2020-07-07 2023-08-10 Sichuan Haisco Pharmaceutical Co., Ltd. Compound having btk kinase degrading activity, and preparation method and pharmaceutical use therefor
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
EP4212534A1 (en) * 2020-09-09 2023-07-19 Haisco Pharmaceuticals Pte. Ltd. Salt of compound for degrading btk, crystal form thereof, and use thereof in medicine
WO2022111449A1 (en) * 2020-11-25 2022-06-02 四川海思科制药有限公司 Preparation method for btk degradation agent
CN116323594A (en) * 2020-11-25 2023-06-23 四川海思科制药有限公司 Preparation method of BTK degradation agent
WO2022111447A1 (en) * 2020-11-25 2022-06-02 四川海思科制药有限公司 Method for preparing btk degrading agent
WO2022253250A1 (en) * 2021-06-01 2022-12-08 正大天晴药业集团股份有限公司 Bruton's tyrosine kinase degrader containing fused-ring or spiro-ring
CN115521313B (en) * 2021-06-24 2023-11-03 山东大学 Compound for degrading BTK protein and preparation method and application thereof
US11767330B2 (en) 2021-07-06 2023-09-26 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
EP4385985A1 (en) 2021-08-11 2024-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Heterocyclic derivative, and composition and pharmaceutical use thereof
WO2023023537A1 (en) * 2021-08-17 2023-02-23 Endotarget Inc. Compounds and methods for the targeted degradation of bruton's tyrosine kinase
WO2023072270A1 (en) * 2021-10-29 2023-05-04 百极弘烨(南通)医药科技有限公司 Protac compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
WO2023125907A1 (en) * 2021-12-30 2023-07-06 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2024127022A1 (en) * 2022-12-14 2024-06-20 Oxford University Innovation Limited Heterocyclic compounds targeting the nudt5 protein

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands
US8153659B2 (en) * 2007-03-20 2012-04-10 Celgene Corporation 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
MX2012008643A (en) * 2010-01-27 2013-02-26 Vertex Pharma Pyrazolopyrimidine kinase inhibitors.
AU2011269989B2 (en) 2010-06-23 2014-12-11 Hanmi Science Co., Ltd. Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
JP2014515345A (en) * 2011-01-10 2014-06-30 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pyrimidinone derivatives as fatty acid synthase inhibitors
EP2687511A1 (en) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinone derivatives as tissue transglutaminase inhibitors
PE20151981A1 (en) * 2013-04-30 2016-01-14 Glaxosmithkline Ip No 2 Ltd ZESTE APPROVAL INHIBITOR PONTENCER
CA2917735C (en) * 2013-07-11 2017-04-18 Betta Pharmaceuticals Co., Ltd Protein tyrosine kinase modulators and methods of use
AR101106A1 (en) 2014-07-02 2016-11-23 Pharmacyclics Llc BRUTON THYROSINE QUINASE INHIBITORS
CN104530046B (en) * 2014-12-10 2016-08-24 广东东阳光药业有限公司 Diaza spiro compounds and the application in medicine thereof
EP3337802A1 (en) * 2015-08-17 2018-06-27 Lupin Limited Heteroaryl derivatives as parp inhibitors
WO2017054702A1 (en) * 2015-09-28 2017-04-06 四川海思科制药有限公司 Biphenyl derivative and preparation method and use thereof in medicine
GB201517217D0 (en) * 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CA3001799A1 (en) * 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
WO2017156495A1 (en) * 2016-03-11 2017-09-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating bruton's tyrosine kinase
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197055A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
IL293319A (en) 2016-08-16 2022-07-01 Beigene Ltd Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo(1,5-a)pyrimidine-3- carboxamide, preparation, and uses thereof
GB201614134D0 (en) 2016-08-18 2016-10-05 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN106831787B (en) * 2017-01-20 2018-10-23 成都倍特药业有限公司 Compound and its preparation method and application as bruton's tyrosine kinase inhibitor
TWI754011B (en) * 2017-02-24 2022-02-01 美商基利科學股份有限公司 Inhibitors of bruton's tyrosine kinase
CN109422752B (en) * 2017-09-03 2023-04-07 上海美志医药科技有限公司 Compound with functions of inhibiting and degrading Bruton tyrosine protein kinase Btk activity
CN109422696B (en) * 2017-09-04 2020-10-30 北京睿熙生物科技有限公司 Inhibitors of bruton's tyrosine kinase
WO2019127008A1 (en) * 2017-12-26 2019-07-04 清华大学 Compound for targeted degradation of btk and application thereof
CN108191871B (en) * 2018-01-02 2020-02-18 成都倍特药业有限公司 Novel Bruton's tyrosine kinase inhibitor and preparation method and application thereof
EP3978496A4 (en) * 2019-05-31 2022-08-17 Haisco Pharmaceuticals Pte. Ltd. Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof

Also Published As

Publication number Publication date
TWI762939B (en) 2022-05-01
MX2021012756A (en) 2022-04-18
US11542266B1 (en) 2023-01-03
EP3978496A1 (en) 2022-04-06
JP2022534650A (en) 2022-08-03
TW202110825A (en) 2021-03-16
KR20220016049A (en) 2022-02-08
CN113544130B (en) 2024-01-09
EP3978496A4 (en) 2022-08-17
CN113544130A (en) 2021-10-22
IL287332A (en) 2021-12-01
BR112021024131A2 (en) 2022-01-11
CA3133004A1 (en) 2020-12-03
AU2020281410A1 (en) 2021-10-07
WO2020239103A1 (en) 2020-12-03
CN118027041A (en) 2024-05-14

Similar Documents

Publication Publication Date Title
IL287332A (en) Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
SG11202006409TA (en) Biaryl derivative, preparation method therefor and pharmaceutical use thereof
SG11202105850YA (en) Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof
EP3486242A4 (en) Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof
EP3632907A4 (en) N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
EP3466962A4 (en) Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof
EP3805231A4 (en) Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
IL276244A (en) Ophthalmic pharmaceutical composition, preparation method therefor and application thereof
EP4056571A4 (en) Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
ZA202202932B (en) Fxia inhibitors and preparation method therefor and pharmaceutical use thereof
EP3653202A4 (en) Pharmaceutical preparation and preparation method therefor
EP4079734A4 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP3623503A4 (en) Multispecific protein drug and library thereof, preparing method therefor and application thereof
EP3450450A4 (en) Vancomycin derivative, preparation method, pharmaceutical composition and use thereof
EP3406606A4 (en) Nitrogenous heterocyclic amide derivative, preparation method thereof, and pharmaceutical application
IL282218A (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
IL276311A (en) Methyllactam ring compound and pharmaceutical use thereof
EP3988547A4 (en) Indazole derivative, preparation method therefor, and pharmaceutical application thereof
IL291557A (en) An antibody, a pharmaceutical composition, and a method
EP4071170A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
EP3851438A4 (en) Btk inhibitor, pharmaceutically acceptable salt, polymorph and application thereof
EP3805212A4 (en) 3-oxazolinone compound, preparation method therefor and pharmaceutical application thereof
EP3858812A4 (en) Mdm2 inhibitor, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP4067349A4 (en) Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof
EP3903815A4 (en) Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof